← back to search

Jun Zhu

University of California, San Francisco · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Prostate Cancer Treatment and Research, Bladder and Urothelial Cancer Treatments, Lung Cancer Research Studies, and Peptidase Inhibition and Analysis.
h-index
17
citations
1,023
works
235
NIH funding
primary concept
email

Recent publications

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer
Nature Communications 2025cited by 6position: middledoi
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Nature Genetics 2025cited by 3position: middledoi
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Clinical Cancer Research 2024cited by 17position: middledoi
PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Molecular Cancer Therapeutics 2024cited by 13position: middledoi
Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)
Chinese Journal of Cancer Research 2024cited by 10position: middledoi
Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Blood 2024cited by 2position: lastdoi
Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
Blood 2023cited by 2position: lastdoi
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
European Urology Oncology 2022cited by 84position: middledoi
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Cancer Research 2022cited by 57position: middledoi
Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)
Frontiers in Oncology 2022cited by 18position: lastdoi
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Clinical Cancer Research 2021cited by 154position: middledoi
Relationship between thioredoxin-interacting protein (TXNIP) and islet β-cell dysfunction in patients with impaired glucose tolerance and hypertriglyceridemia.
PubMed 2015cited by 16position: middle

Grants

Collaborative Research: RI: Medium: Understanding, Visualizing, and Attributing Multimodal Generative Models
NSF2403303$400,0002024–2028PIRePORTER
CAREER: Exploiting Deep Generative Models for Visual Recognition
NSF2239076$462,5672023–2028PIRePORTER
NSF/DMR-BSF: Quantum Transport in a Helical One-Dimensional System
NSF1904986$456,2602019–2023PIRePORTER
Probing Charge, Spin and Thermoelectric Transport in Atomically Thin Materials
NSF1708972$432,2032017–2021PIRePORTER
Convergent Research: NSF/DOE Quantum Science Summer School
NSF1743079$157,5642017–2022PIRePORTER
Controlling Valley and Spin-Orbit Coupling in Graphene and Bilayer Graphene Nanostructures
NSF1506212$438,1902015–2018PIRePORTER
CAREER: Mesoscopic Phenomena and Band-Structure Engineering in Single-Layer and Bilayer Graphene
NSF0748604$500,0002008–2014PIRePORTER

Frequent collaborators

Jonathan Chou · UCSF Helen Diller Family Comprehensive Cancer Center5 papers (2021–2025)Felix Y. Feng · Polytechnique Montréal4 papers (2021–2025)Terence W. Friedlander · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2021–2025)Carissa Chu · Memorial Sloan Kettering Cancer Center3 papers (2021–2025)Emily A. Egusa · University of Minnesota3 papers (2021–2024)Vadim S. Koshkin · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2021–2025)Sima P. Porten · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2021–2025)Michelle L. Badura · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2021–2024)Raj S. Pruthi · University of North Carolina at Chapel Hill2 papers (2021–2022)Henry M. Delavan · University of California, San Francisco2 papers (2024–2025)Maxwell V. Meng · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2021–2022)Ewan A. Gibb · University of British Columbia2 papers (2021–2022)Veronica Steri · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2024–2025)Martin Sjöström · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2021–2022)Bradley A. Stohr · City College of San Francisco2 papers (2021–2022)Yair Lotan · Cancer Research Center2 papers (2021–2022)Roshan Lodha · Cleveland Clinic Lerner College of Medicine2 papers (2024–2025)Emily Chan · Chulalongkorn University2 papers (2022–2025)Peter C. Black · Prevention of Organ Failure2 papers (2021–2022)David M. Wilson · University of California, San Francisco1 papers (2024–2024)